Zacks Investment Research
01 Jul 2026, 15:45 UTC · 11w ago
Verdict
Headline leans bullish. We score COLL +0.90 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Collegium Pharmaceutical raised its 2026 product revenue guidance to a range of $865-$895 million from the previous $805-$825 million.
More positive than 92% of claims this week
The company completed the acquisition of Azstarys from Corium Therapeutics, which is expected to be immediately accretive to earnings.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
Jornay PM sales increased 36% year over year in Q1 2026, with prescriptions rising 14% to over 206,000.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported strong growth in its ADHD franchise, completed a strategic acquisition, and raised its 2026 financial guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−37.1%
Price is moving against the score
$22.77 vs $36.20 close before publication (Jun 30) · not market-adjusted
COLL chart →
